Power Law company profile

Dyne Therapeutics

Biotech & Life Sciences · Waltham, United States · Founded 2017 · IPO 2020 Unicorn

Dyne Therapeutics is a new biotechnology company pioneering targeted therapies for patients with serious muscle diseases

Valuation

$1.96B

Market cap · May/2026

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026

Investors

10 investors on Dyne Therapeutics's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Seed 1 investor entered at this stage

RA Capital Management

Series A 9 investors entered at this stage

MPM BioImpact

Forbion Capital Partners

Logos Capital

Atlas Venture

Wellington Management

Citadel

Cure Duchenne

Franklin Templeton Investments

Vida Ventures

Global footprint

Where Dyne Therapeutics has talent and traffic

Workforce by country

🇺🇸 United States · Waltham HQ

Book a demo for the full country breakdown

Web traffic by country

21K monthly visits
across markets

🇺🇸 United States86.7%

🇮🇳 India6.2%

🇬🇧 United Kingdom6.2%

🏳️ Korea1.4%

🏳️ Republic of1%

Top 5 markets shown

Market sentiment

What the market is saying about Dyne Therapeutics

An AI-synthesized read of the highest-engagement posts about Dyne Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Dyne Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles